Real-world effectiveness of primary screening with high-risk human papillomavirus testing in the cervical cancer screening programme in China: a nationwide, population-based study

Table 4 The detection rates of precancerous lesions or cancer in HPV-positive women

	HPV testing with genotyping triage		HPV testing with cytology triage
	HPV-16/18	Non-16-18 HPV genotypes	HPV testing with cytology triage
Women who attended immediate colposcopy adherence to the protocol^a
CIN2+, n/N (%)	1922/13 488 (17.3)	902/7167 (13.8)	870/4127 (24.1)
aOR (95% CI)	1.32 (1.22–1.43)	Ref (1.00)	1.96 (1.77–2.16)
Colposcopies per CIN2+ detection	5.8	7.2	4.1
CIN2 or 3, n/N (%)	1736/13 488 (15.6)	861/7167 (13.1)	785/4127 (21.8)
aOR (95% CI)	1.24 (1.14–1.34)	Ref (1.00)	1.82 (1.64–2.01)
ICC, n/N (%)	186/13 488 (1.7)	41/7167 (0.6)	85/4127 (2.4)
aOR (95% CI)	2.75 (2.00–3.78)	Ref (1.00)	3.64 (2.55–5.20)
Women who needed intensified screening but attended immediate colposcopy ^b
CIN2+, n/N (%)	NA	102/3507 (2.9)	83/1673 (5.0)
aOR (95% CI)	NA	Ref (1.00)	1.92 (1.38–2.67)
Colposcopies per CIN2+ detection	NA	34.5	20.0
CIN2 or 3, n/N (%)	NA	91/3507 (2.6)	67/1673 (4.0)
aOR (95% CI)	NA	Ref (1.00)	1.68 (1.18–2.39)
ICC, n/N (%)	NA	11/3507 (0.3)	16/1673 (1.0)
aOR (95% CI)	NA	Ref (1.00)	3.94 (1.61–9.63)

Note: HPV human papillomavirus, aOR adjusted odds ratio, CI confidential interval, CIN2+ cervical intraepithelial neoplasia 2 grade or worse, ICC invasive cervical cancer, Ref reference, NA not applicable. ^aThese women included those who were HPV-16 or HPV-18 positive, non-16-18 high-risk HPV positive with abnormal cytology, and any HPV positive with abnormal cytology. ^bThese women included those who were non-16-18 high-risk HPV positive with negative cytology and any HPV positive with negative cytology. aOR was calculated by using multivariate logistic regression adjusted for age, ever screening, and income classification

ISSN: 1741-7015